|Bid||0.0000 x 800|
|Ask||0.0000 x 1000|
|Day's Range||0.6600 - 0.7280|
|52 Week Range||0.2000 - 2.6000|
|Beta (3Y Monthly)||4.97|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 7, 2018 - Mar 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.17|
Sunesis Pharmaceuticals, Inc. (SNSS) today announced the presentation of results from the Company’s Phase 1b/2 clinical trial of its non-covalent BTK inhibitor vecabrutinib in adults with relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell malignancies. The results are being presented today, June 15, from 5:30-7:00 p.m. CET in a poster session titled “Chronic lymphocytic leukemia and related disorders – Clinical” at the 24th Congress of the European Hematology Association (EHA) in Amsterdam. The poster, titled “Preliminary Results of a Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton’s Tyrosine Kinase Inhibitor (BTKi) Vecabrutinib in B-Cell Malignancies,” Abstract No. PS1148, is available at www.sunesis.com.
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs June 12) • Abbott Laboratories (NYSE: ABT ) • Avedro ...
Biotech stocks staged a steady recovery last week. ASCO presentations dominated the headlines, with Iovance Biotherapeutics Inc (NASDAQ: IOVA ) and Mirati Therapeutics Inc (NASDAQ: MRTX ) among the biggest ...
On a per-share basis, the South San Francisco, California-based company said it had a loss of 10 cents. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by ...
Phase 1b/2 Trial of Vecabrutinib Advances into 200 mg Cohort Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., May 08, 2019 --.
Sunesis Pharmaceuticals' (SNSS) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, vecabrutinib.
Sunesis Pharmaceuticals, Inc. (SNSS) today announced that it will host a conference call on Wednesday, May 8th, 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the first quarter ended March 31, 2019. To access the live audio webcast, or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at http://ir.sunesis.com. The webcast will be recorded and available for replay on the company's website for two weeks.
Sunesis Pharmaceuticals, Inc. (SNSS) today announced that it has entered into a $5.5 million loan agreement with Silicon Valley Bank. The new agreement allows the company to retire its existing loan and defer any principal repayment on the new loan for more than 18 months. The new facility includes interest-only payments through 2020, with principal repayment over 24 months beginning in 2021, as well as a lower interest rate than the previous loan.
This predicted growth is an indicator that more people will soon need access to quality medical care and the healthcare sector must be aptly prepared. As the healthcare sector continues to progress into the future, investors interested in potentially lucrative opportunities could benefit from focusing on this sector. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Shineco Inc (TYHT), Tonix Pharmaceuticals Holding Corp (TNXP), and Sunesis Pharmaceuticals Inc (SNSS) are 4 healthcare companies worth keeping on your radar.
Sunesis Pharmaceuticals, Inc. (SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President, Finance and Corporate Development of Sunesis, will present at the Needham & Company 18th Annual Healthcare Conference on Wednesday, April 10, 2019 at 2:10 PM Eastern Time at the Westin Grand Central Hotel in New York City. Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase inhibitor pipeline, with an emphasis on its oral non-covalent BTK inhibitor vecabrutinib.
The Zacks Analyst Blog Highlights: Roche, Celgene, Johnson and Johnson, Bayer and Sunesis Pharmaceuticals
LONDON, UK / ACCESSWIRE / March 22, 2019 / Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) is currently in the dose-escalation portion of the Phase Ib/II study of its BTK inhibitor vecabrutinib, and the first ...
SOUTH SAN FRANCISCO, Calif., March 07, 2019 -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the fourth quarter and year ended December 31,.
SOUTH SAN FRANCISCO, Calif., March 04, 2019 -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Company will participate in three upcoming investor.
Puma Biotech (PBYI) betters loss estimates in Q4 and also rides high on revenue beat. Nerlynx impresses with strong sequential and year-over-year growth.
Sunesis Pharmaceuticals, Inc. (SNSS) today announced that it will host a conference call on Thursday, March 7th, 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the fourth quarter and year ended December 31, 2018. To access the live audio webcast, or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at http://ir.sunesis.com. The webcast will be recorded and available for replay on the company's website for two weeks.
Agios' (AGIO) loss tops estimates in Q4. Its precision medicine Tibsovo receives the FDA nod and leads to significant year-over-year revenue growth.
Acorda (ACOR) rides high on earnings and revenue beat in Q4. The company plans the US launch of Inbrija in first-quarter 2019.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Jan. 17) Avenue Therapeutics Inc (NASDAQ: ATXI ) BioSpecifics ...
Sunesis Pharmaceuticals, Inc. (SNSS) today announced the pricing of underwritten public offerings of (i) 23,000,000 shares of its common stock and (ii) 17,000 shares of its non-voting Series E Convertible Preferred Stock (“Series E Stock”). The public offering price of each share of common stock is $0.50 and the public offering price of each share of Series E Stock, convertible into 1,000 shares of common stock, is $500. Sunesis has granted the underwriters a 30 day option to purchase up to an additional 3,450,000 shares of common stock to cover over-allotments, if any.